International cost-effectiveness analysis of chemoradiotherapy plus pembrolizumab for locally advanced cervical cancer
At current prices, pembrolizumab-CCRT represents a cost-effective alternative for patients with LACC in the USA and China, but not in Italy.
Authors
- Youwen Zhu (ORCID: https://orcid.org/0000-0001-8692-3591)
- Hong Zhu (ORCID: https://orcid.org/0000-0002-3659-8070)
- Kun Liu (ORCID: https://orcid.org/0000-0001-6720-3310)
Institutions
- Central South University (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.3802/jgo.2025.36.e106
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00